Mazdutide vs Retatrutide
| Attribute | Mazdutide IBI362, GLP-1/Glucagon dual agonist | Retatrutide Triple agonist (GLP-1/GIP/Glucagon) |
|---|---|---|
| Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
| Best known for | GLP-1/glucagon dual agonist weight-loss research | Triple-receptor metabolic research |
| In plain English | GLP-1 reduces appetite; glucagon raises energy expenditure. Together they aim for more weight loss than GLP-1 alone. | Retatrutide pulls three levers — appetite, insulin response, and energy expenditure via glucagon. Trials have shown the largest weight reductions of any incretin to date. |
| How it works | Dual activation of GLP-1 receptors (satiety, insulin) and glucagon receptors (lipolysis, thermogenesis). | GLP-1 reduces appetite. GIP enhances insulin response. Glucagon receptor activation increases energy expenditure and fat oxidation. |
| Researchers study | Obesity and metabolic-associated liver disease, particularly in Chinese clinical research. | Obesity, hepatic steatosis, and metabolic syndrome. |
| Internet discussion | Discussed alongside survodutide and retatrutide in next-gen metabolic research. | Treated as the 'next big thing' in metabolic forums. Discussion centers on side effect profile vs tirzepatide. |
Mazdutide
GLP-1/glucagon dual agonist weight-loss research
GLP-1 reduces appetite; glucagon raises energy expenditure. Together they aim for more weight loss than GLP-1 alone.
Dual activation of GLP-1 receptors (satiety, insulin) and glucagon receptors (lipolysis, thermogenesis).
Obesity and metabolic-associated liver disease, particularly in Chinese clinical research.
Discussed alongside survodutide and retatrutide in next-gen metabolic research.
Mazdutide is a GLP-1/glucagon dual agonist researched for obesity and metabolic disease.
Retatrutide
Triple-receptor metabolic research
Retatrutide pulls three levers — appetite, insulin response, and energy expenditure via glucagon. Trials have shown the largest weight reductions of any incretin to date.
GLP-1 reduces appetite. GIP enhances insulin response. Glucagon receptor activation increases energy expenditure and fat oxidation.
Obesity, hepatic steatosis, and metabolic syndrome.
Treated as the 'next big thing' in metabolic forums. Discussion centers on side effect profile vs tirzepatide.
Retatrutide is an investigational triple agonist showing the largest weight-loss signals in metabolic research to date.